Cephalon

TRUXIMA

Manufacturer:

Cephalon

Truxima HCPCS:

Q5115

HCPCS Code Descriptor:

Injection, rituximab-abbs, biosimilar, (truxima), 10 mg

Category:

Q Code

Truxima NDCs:

63459-0104-50, 63459-0103-10

Primary Type:

Oncology Biosimilar

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Truxima:

TRUXIMA is an Oncology Biosimilar drug manufactured by Cephalon and administered via the Intravenous route of administration. The Q Code: Q5115 is aligned to the drug TRUXIMA.

Truxima is used to treat certain types of cancer, joint pain, certain blood vessel diseases, and a certain skin condition. Truxima works by slowing down or stopping the growth of certain cells, which can be cancer-causing. Truxima is a branded drug manufactured by Cephalon and is a biosimilar to the reference product Rituxan (J9312). Patient assistance programs for this medication can be found through Teva pharmaceuticals.

ACCESS PRICING AND MORE BY REGISTERING

Q5115 Added Date:

July 1, 2019

Q5115 Effective Date:

July 1, 2019

Q5115 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Truxima billing and coding information.
Truxima patient assistance information can be found through Teva Support Solutions at the URL: https://www.truximahcp.com/support-resources
TRUXIMA prescribing information can be found at the link below:
Information regarding TRUXIMA’s side effects can be found at MedlinePlus